# Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

> **NCT03992417** · — · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 955 (actual)

## Conditions studied

- Dermatitis Atopic

## Interventions

- **DRUG:** Dupilumab SAR231893 (REGN668)

## Key facts

- **NCT ID:** NCT03992417
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-11
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 955 (ACTUAL)
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992417, "Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03992417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*